Melanoma - selumetinib - BRAF mutation

Association details:

Biomarker:	BRAF mutation
Cancer:	Melanoma
Drug:	Koselugo (selumetinib) (MEK inhibitor)
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: C2 – Inclusion Criteria

Source:

clinicaltrials.gov

Title:

Docetaxel With or Without AZD6244 in Melanoma

Excerpt:

...- Able to provide evidence from an accredited laboratory of wt BRAF status for their melanoma, or ascertainment of wt BRAF status from a sample of melanoma provided for mutational analysis in Oxford....

Trial ID:

NCT01256359

Evidence Level:

Sensitive: C2 – Inclusion Criteria

Source:

clinicaltrials.gov

Title:

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

Excerpt:

...- Tumor sample confirmed as BRAF mutation positive...

Trial ID:

NCT00936221

More C2 evidence

Evidence Level:

Sensitive: C2 – Inclusion Criteria

Source:

clinicaltrials.gov

Title:

Randomised Study to Compare the Efficacy of AZD6244 vs TMZ

Excerpt:

...Assessment of the safety and tolerability of AZD6244`Investigation of the pharmacokinetics of AZD6244`Assessment of the efficacy of AZD6244 versus temozolomide in patients who are BRAF and BRAF and /or NRAS mutation positive...

Trial ID:

NCT00338130

Evidence Level:

Sensitive: C2 – Inclusion Criteria

Source:

clinicaltrialsregister.eu

Title:

A double blind randomised phase 2 trial of docetaxel with or without AZD6244 in wt BRAF advanced melanoma

Excerpt:

...BRAF Mutation Screening• In the opinion of the investigator the patient is likely to fulfil the eligibility criteria of the main studyMain Study• ≥ 16 years of age, written informed consent• Histologically confirmed, wild type BRAF, metastatic melanoma.• Unresectable Stage III or Stage IV metastatic melanoma.• Measurable disease as defined by modified RECIST criteria. ...

Trial ID:

2009-018153-23

Evidence Level:

Sensitive: D – Preclinical

Source:

Oncotarget

Title:

Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade

Excerpt:

Responsiveness to BRAF-V600E-, MEK1/2- or PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cell lines….Responsiveness profiles of BRAF-mutant human melanoma cell lines to BRAFV600E-, MEK1/2-, and PI3K/mTOR-specific inhibitors are significantly correlated.

DOI:

10.18632/oncotarget.6600